
Opinion|Videos|August 4, 2026
How Does Solriamfetol's DNRI Mechanism Differ From Other Wakefulness Agents?
Winter explains solriamfetol's distinct pharmacological profile as a dopamine-norepinephrine reuptake inhibitor—the first and only agent in its class approved specifically for EDS—and discusses why this mechanism matters clinically compared to other available wakefulness-promoting options.
Advertisement
Episodes in this series
Winter explains solriamfetol's distinct pharmacological profile as a dopamine-norepinephrine reuptake inhibitor—the first and only agent in its class approved specifically for EDS—and discusses why this mechanism matters clinically compared to other available wakefulness-promoting options.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
2
Pharmacists Are Critical to SGLT2, GLP-1 Use in CKD
3
A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea
4
Learning Curves Don't Come With a Package Insert
5






































































































